Rethinking treatment de-escalation in elderly glioblastoma: Lessons from a multicenter real-world cohort
{{output}}
Background: Glioblastoma (GBM) in elderly patients (≥65 years) carries a poor prognosis and higher treatment toxicity. Consequently, many receive de-escalated regimens, often guided by MGMT promoter methylation. However, real-wo... ...
